The DOI matches its Crossref record.
Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years
Abstract
Superparamagnetic iron oxide (SPIO) particles are a potent new class of MR contrast agents affording improved detection of hepatic and splenic neoplasms. In this report we review the development of this agent through preclinical studies and early clinical results at Massachusetts General Hospital during a 5-year investigation. SPIO particles are sequestered by normal phagocytic Kupffer cells of the reticuloendothelial system (RES) but are not retained in tumor tissue. Consequently, there is a fivefold increase in T2 relaxation between normal RES tissue and tumor, with a comparable advantage in quantitative signal-to-noise ratio, contrast-to-noise ratio, and lesion detectability in the liver and spleen on MR imaging. Increased lesion conspicuity can be exploited to decrease threshold size for lesion detection to less than 3 mm. Clinically beneficial effects occur with a variety of mildly T2-weighted spin-echo pulse sequences; gradient-echo techniques show even greater benefit after administration of SPIO. Metabolically, pharmaceutical-grade preparations are biodegradable and bioavailable, being rapidly turned over into body iron stores and incorporated into erythrocyte hemoglobin. Early dose-escalation clinical trials have identified a probable clinical dose range of 10-20 mumols Fe/kg body weight. In the United States, SPIO compounds evaluated to date are still approved for use in investigational studies only. Newer commercial formulations currently being evaluated may extend clinical safety margins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Due to their high liver uptake, iron oxide nanoparticles have been employed relatively extensively for visualizing primary lesions in the liver, e.g. in case of hepatocellular carcinoma (HCC) (Figure 3 A, B) as well as liver metastases (Figure 3 C, D) [144, 145].”
From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [145]
Citations
Cited by
Sorted by citations
Edelman, R. R., & Warach, S. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303183281109 · Cited by 1,207
Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications
Dadfar, S. M., Roemhild, K., Drude, N. I., von Stillfried, S., Knüchel, R., Kiessling, F., & Lammers, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.005 · Cited by 1,181
Iron Oxide Based Nanoparticles for Multimodal Imaging and Magnetoresponsive Therapy
Lee, N., Yoo, D., Ling, D., Cho, M. H., Hyeon, T., & Cheon, J. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00112 · Cited by 1,020
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles
Arami, H., Khandhar, A., Liggitt, D., & Krishnan, K. M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00541h · Cited by 830
Lübbe, A. S., Bergemann, C., Riess, H. B., Schriever, F., Reichardt, P., Possinger, K., Matthias, M., Dörken, B., Herrmann, F., Gürtler, R., et al. (1996) · PubMed · Cited by 652
Jung, C. W., & Jacobs, P. M. (1995) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(95)00024-b · Cited by 625
Arbab, A. S., Wilson, L. B., Miller, B. R., Jordan, E. K., Lewis, B. K., Kalish, H. R., & Frank, J. A. (2003) · Radiology · doi:10.1148/radiol.2293021215 · Cited by 552
Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI
Arbab, A. S., Yocum, G. T., Kalish, H. R., Jordan, E. K., Anderson, S. A., Khakoo, A. Y., Read, E. J., & Frank, J. A. (2004) · Blood · doi:10.1182/blood-2004-02-0655 · Cited by 529
“When used for hepatic MRI, the iron is phagocytosed and accumulates in endosomes of Kupffer cells and reticuloendothelial cells ((13)).”
BackgroundMultifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics
Zhao, S., Yu, X., Qian, Y., Chen, W., & Shen, J. (2020) · Theranostics · doi:10.7150/thno.42564 · Cited by 391
“Meanwhile, appropriate surface modification can also import the Fe3O4 NPs with better biocompatibility, long blood circulation and further functionalization, such as active targeting ability [105, 117].”
BackgroundMethodInfluentialArbab, A. S., Wilson, L. B., Ashari, P., Jordan, E. K., Lewis, B. K., & Frank, J. A. (2005) · NMR in Biomedicine · doi:10.1002/nbm.970 · Cited by 347
Towards clinically translatable in vivo nanodiagnostics
Park, S.-M., Aalipour, A., Vermesh, O., Yu, J. H., & Gambhir, S. S. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.14 · Cited by 330
Magnetic Particle Imaging (MPI) for NMR and MRI researchers
Sarıtaş, E. Ü., Goodwill, P. W., Croft, L. R., Konkle, J., Lu, K., Zheng, B., & Conolly, S. (2012) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2012.11.029 · Cited by 308
“SPIO contrast agents are processed in the liver rather than the kidneys [19,20], and have been shown to be safe for CKD patients [21].”
Burlec, A. F., Corciovă, A., Boev, M., Batir, D. M., Mircea, C., Cioancă, O., Danila, G., Dănilă, D. M., Bucur, A. F., & Hăncianu, M. (2023) · Pharmaceuticals · doi:10.3390/ph16101410 · Cited by 329
“In this regard, Ferrucci, Marchal and Deng used this feature to visualize the primary lesions of the liver in cases of hepatocellular carcinoma and liver metastases [190–192].”
BackgroundCT and MR Imaging of Benign Hepatic and Biliary Tumors
Horton, K. M., Bluemke, D. A., Hruban, R. H., et al. (1999) · Radiographics · doi:10.1148/radiographics.19.2.g99mr04431 · Cited by 284
A multicenter validation of an active contour-based left ventricular analysis technique
Graves, M. J., Berry, E., Eng, A. A. B., Westhead, M., Black, R. T., Beacock, D. J., Kelly, S., & Niemi, P. (2000) · Journal of Magnetic Resonance Imaging · doi:10.1002/1522-2586(200008)12:2 · Cited by 21
Terrovitis, J. V., Stuber, M., Youssef, A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.732073 · Cited by 268
Tracking stem cells using magnetic nanoparticles
Berman, S. M. C., Walczak, P., & Bulte, J. W. M. (2011) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.140 · Cited by 265
Arbab, A. S., Wilson, L. B., Miller, B. R., Jordan, E. K., Bulte, J. W. M., & Frank, J. A. (2003) · Transplantation · doi:10.1097/01.tp.0000089237.39220.83 · Cited by 253
“After intravenous injection, most SPIO nanoparticles accumulate in Kupffer cells and reticuloendothelial cells in the spleen (9).”
BackgroundMR Imaging of Liver Fibrosis: Current State of the Art
Faria, S. C., Ganesan, K., Mwangi, I., et al. (2009) · Radiographics · doi:10.1148/rg.296095512 · Cited by 235
Ward, J., Naik, K. S., Guthrie, J. A., Wilson, D. J., & Robinson, P. J. (1999) · Radiology · doi:10.1148/radiology.210.2.r99fe05459 · Cited by 228
Jung, C. W. (1995) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(95)00023-a · Cited by 224
Hachani, R., Lowdell, M. W., Birchall, M., Hervault, A., Mertz, D., Bégin‐Colin, S., & Thanh, N. T. K. (2015) · Nanoscale · doi:10.1039/c5nr03867g · Cited by 220
Exploiting Endocytosis for NanomedicinesPreprint
Akinc, A., & Battaglia, G. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016980 · Cited by 215
Arbab, A. S., Yocum, G. T., Wilson, L. B., Ashari, P., Jordan, E. K., Kalish, H. R., & Frank, J. A. (2004) · Molecular Imaging · doi:10.1162/153535004773861697 · Cited by 213
“FEs is a dextran-coated SPIO nanoparticle approved for clinical use as an MR contrast agent for hepatic imaging [19].”
BackgroundWu, S., Lin, Y., Hung, Y., Chou, Y., Hsu, Y., Chen, C., & Mou, C. (2007) · ChemBioChem · doi:10.1002/cbic.200700509 · Cited by 209
Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds
Rivera-Gil, P., Hühn, D., del Mercato, L. L., Sasse, D., & Parak, W. J. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.009 · Cited by 202
Hamm, B., Staks, T., Taupitz, M., Maibauer, R., Speidel, A., Huppertz, A., Frenzel, T., Lawaczeck, R., Wolf, K. J., & Lange, L. (1994) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880040508 · Cited by 187
Reimer, P., Jähnke, N., Fiebich, M., Schima, W., Deckers, F., Marx, C., Holzknecht, N., & Saini, S. (2000) · Radiology · doi:10.1148/radiology.217.1.r00oc31152 · Cited by 188
Petersein, J., Spinazzi, A., Giovagnoni, A., et al. (2000) · Radiology · doi:10.1148/radiology.215.3.r00jn14727 · Cited by 187
In Vivo Trafficking and Targeted Delivery of Magnetically Labeled Stem Cells
Arbab, A. S., Jordan, E. K., Wilson, L. B., Yocum, G. T., Lewis, B. K., & Frank, J. A. (2004) · Human Gene Therapy · doi:10.1089/104303404322959506 · Cited by 176
“Ferumoxide is one of the SPIOs that are routinely used as a contrast agent for reticuloendothelial systems (Ferrucci and Stark, 1990).”
T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning
SIMON, G. H., Bauer, J. S., Saborowski, O., Fu, Y., Corot, C., Wendland, M. F., & Daldrup-Link, H. E. (2005) · European Radiology · doi:10.1007/s00330-005-0031-2 · Cited by 172
“Superparamagnetic iron oxide nanoparticles have been introduced as contrast agents for magnetic resonance (MR) imaging because of their strong T2 relaxivity, which leads to a strong decrease in signal intensity (negative enhancement) of various target organs on T2-weighted images [1, 2].”
BackgroundMR Contrast Agents for Liver Imaging: What, When, How
Gandhi, S. N., Brown, M. A., Wong, J. G., Aguirre, D. A., & Sirlin, C. B. (2006) · Radiographics · doi:10.1148/rg.266065014 · Cited by 164
Kresse, M., Wagner, S., Pfefferer, D., Lawaczeck, R., Elste, V., & Semmler, W. (1998) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910400209 · Cited by 161
In Vivo Imaging of Immune Rejection in Transplanted Pancreatic Islets
Evgenov, N. V., Medarova, Z. O., Pratt, J., Pantazopoulos, P., Leyting, S., Bonner‐Weir, S., & Moore, A. V. (2006) · Diabetes · doi:10.2337/db06-0484 · Cited by 159
“When used for hepatic MRI, the iron oxide nanoparticles are phagocytosed and accumulate in the endosomes of Kuppfer cells and reticuloendothelial cells (18).”
BackgroundMesoporous silica nanoparticles: A multifunctional nano therapeutic system
Mai, W. X., & Meng, H. (2012) · Integrative Biology · doi:10.1039/c2ib20137b · Cited by 163
Biodistribution and toxicity of MR imaging contrast media
Øksendal, A. N., & Hals, P. (1993) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880030128 · Cited by 156
Madru, R., Kjellman, P., Olsson, F., Wingårdh, K., Ingvar, C., Ståhlberg, F., Olsrud, J., Lätt, J., Fredriksson, S., Knutsson, L., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.092437 · Cited by 154
Tang, Y., Yamashita, Y., Arakawa, A., et al. (1999) · American Journal of Roentgenology · doi:10.2214/ajr.172.6.10350287 · Cited by 151
On-demand drug delivery from local depots
Brudno, Y., & Mooney, D. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.011 · Cited by 148
Diffusion-weighted Imaging of the Liver: Technical Challenges and Prospects for the Future
Naganawa, S., Kawai, H., Fukatsu, H., Sakurai, Y., Aoki, I., Miura, S., Mimura, T., Kanazawa, H., & Ishigaki, T. (2005) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.4.175 · Cited by 147
Ittrich, H., Peldschus, K., Raabe, N., Kaul, M. G., & Adam, G. (2013) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/s-0033-1335438 · Cited by 149
“Analogously to the liver, the accumulation of SPIO in spleen macrophages improves the detection of metastases or rare primary spleen tumors by increasing the lesion-to-spleen contrast [65].”
Affibody-based nanoprobes for HER2-expressing cell and tumor imaging
Gao, J., Chen, K., Miao, Z., Ren, G., Chen, X. S., Gambhir, S. S., & Cheng, Z. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.053 · Cited by 138
Bulte, J. W. M., Ma, L. D., Magin, R. L., et al. (1993) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910290108 · Cited by 137
An x-space magnetic particle imaging scanner
Goodwill, P. W., Lu, K., Zheng, B., & Conolly, S. (2012) · Review of Scientific Instruments · doi:10.1063/1.3694534 · Cited by 128
Superparamagnetic iron oxide nanoparticles forin vivomolecular and cellular imaging
Sharifi, S., Seyednejad, H., Laurent, S., Atyabi, F., Saei, A. A., & Mahmoudi, M. (2015) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1638 · Cited by 126
Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation
Schleich, N., Danhier, F., & Préat, V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.024 · Cited by 124
“Dextran-coated SPIO have been shown to display a blood clearance half-life of about 10 min with uptake by hepatic RES Kupffer cells accounting for 80% of the injected dose whereas encapsulation in liposomes allowed prolonging the blood clearance half-life to 4 h [48].”
Relaxation in X-Space Magnetic Particle Imaging
Croft, L. R., Goodwill, P. W., & Conolly, S. (2012) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2012.2217979 · Cited by 142
“MPI has no ionizing radiation, and the superparamagnetic iron oxide nanoparticle (SPIO) contrast agent is metabolized directly by the liver rather than by the kidneys [4], [5].”
Pawelczyk, E., Arbab, A. S., Pandit, S., Hu, E. S., & Frank, J. A. (2006) · NMR in Biomedicine · doi:10.1002/nbm.1038 · Cited by 120
Recent Advances in Managing Atherosclerosis via Nanomedicine
Chan, C. K. W., Zhang, L., Cheng, C. K., Yang, H., Huang, Y., Tian, X. Y., & Choi, C. H. J. (2017) · Small · doi:10.1002/smll.201702793 · Cited by 118
Schultz, J. F., Bell, J. D., Goldstein, R. M., et al. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0691-2 · Cited by 116
Ariff, B., Lloyd, C., Khan, S., Shariff, M. I. F., Thillainayagam, A. V., Bansi, D. S., Khan, S. A., Taylor-Robinson, S. D., & Lim, A. K. P. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1289 · Cited by 118
Berman, S. M. C., Galpoththawela, C., Gilad, A. A., Bulte, J. W. M., & Walczak, P. (2010) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22613 · Cited by 112
“biodegradable through the normal biochemical pathways for iron metabolism (6).”
BackgroundKedziorek, D., Muja, N., Walczak, P., Ruíz-Cabello, J., Gilad, A. A., Jie, C., & Bulte, J. W. M. (2010) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22290 · Cited by 106
“Gene ontology analysis segregates genes into two major categories: (1) molecular functions of the cell and (2) biologic processes.”
BackgroundPauleit, D. O., Textor, J., Bachmann, R., et al. (2002) · Radiology · doi:10.1148/radiol.2221001599 · Cited by 105
Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles
Elias, A., & Tsourkas, A. (2009) · Hematology · doi:10.1182/asheducation-2009.1.720 · Cited by 104
“As a consequence, SSPIO has been commonly used to improve the detection of splenic tumors.(7) However, it should be noted that there are some malignant lesions that may contain phagocytes, in which case there may be no differential uptake compared with normal liver parenchyma.”
MethodOleyl-Chitosan Nanoparticles Based on a Dual Probe for Optical/MR Imaging in Vivo
Lee, C., Jang, D., Kim, J., et al. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100241a · Cited by 102
Lee, P.-W., Hsu, S., Wang, J., Tsai, J.-S., Lin, K., Wey, S., Chen, F., Lai, C., Yen, T., & Sung, H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.010 · Cited by 102
“The RES cells, such as the liver RES Kupffer cells, have a scavenging function and, by phagocytosis, readily remove particulate materials from the circulation [30].”
BackgroundLapusan, R., Borlan, R., & Focşan, M. (2024) · Nanoscale Advances · doi:10.1039/d3na01064c · Cited by 119
Cao, C., Wang, X., Cai, Y., Sun, L., Tian, L., Wu, H., He, X., Lei, H. C., Liu, W., Chen, G., et al. (2014) · Advanced Materials · doi:10.1002/adma.201304544 · Cited by 97
Magnetic Resonance Imaging of Focal Liver Lesions
Vogl, T. J., Hammerstingl, R., Schwarz, W., Kümmel, S., Müller, P., Balzer, T., Lauten, M., Balzer, J. O., Mack, M. G., Schimpfky, C., et al. (1996) · Investigative Radiology · doi:10.1097/00004424-199611000-00004 · Cited by 98
Diagnostic nanocarriers for sentinel lymph node imaging
Jain, R. D., Dandekar, P. P., & Patravale, V. B. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.05.010 · Cited by 92
Jasmin, J., Torres, A. L. M., Nunes, H. M. P., Passipieri, J. A., Jelicks, L. A., Gasparetto, E. L., Spray, D. C., de Carvalho, A. C. C., & Méndez‐Otero, R. (2011) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-9-4 · Cited by 91
“The nanoparticles are phagocytosed and accumulate in endosomes of Kupffer cells and reticuloendothelial cells [26].”
BackgroundKim, Y. K., Lee, J. M., Kim, C. S., et al. (2004) · European Radiology · doi:10.1007/s00330-004-2570-3 · Cited by 88
“media such as superparamagnetic iron oxide (SPIO) [8–16],”
BackgroundImaging of brain iron by magnetic resonance: T2 relaxation at different field strengths
Schenck, J. F. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00203-e · Cited by 85
Low drive field amplitude for improved image resolution in magnetic particle imaging
Croft, L. R., Goodwill, P. W., Konkle, J., Arami, H., Price, D. A., Li, A. X., Sarıtaş, E. Ü., & Conolly, S. (2015) · Medical Physics · doi:10.1118/1.4938097 · Cited by 86
Demšar, F., Roberts, T. P. L., Schwickert, H. C., et al. (1997) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910370216 · Cited by 82
Wu, E. X., Tang, H., & Jensen, J. H. (2004) · NMR in Biomedicine · doi:10.1002/nbm.923 · Cited by 79
Oberdick, S. D., Jordanova, K. V., Lundstrom, J. T., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38222-6 · Cited by 80
Frate, C. D., Bazzocchi, M., Mortelé, K. J., et al. (2002) · Radiology · doi:10.1148/radiol.2253011854 · Cited by 80
Nanotechnology and Mri Contrast Enhancement
Matson, M. L., & Wilson, L. J. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.3 · Cited by 80
Kim, M., Kim, J. H., Chung, J. B., et al. (2003) · Radiology · doi:10.1148/radiol.2283020735 · Cited by 79
Jan, T., Shen, Wang, C., & Liao (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s21019 · Cited by 79
Engelhardt, R., Langkowski, J., Fischer, R., et al. (1994) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(94)91230-t · Cited by 77
Nanoparticles for the Optical Imaging of Tumor selectin
Funovics, M. A., Montet, X., Reynolds, F., Weissleder, R., & Josephson, L. (2005) · Neoplasia · doi:10.1593/neo.05352 · Cited by 75
“Although magnetic nanoparticles accumulate in the normal liver, spleen, and lymph nodes [27–31], their accumulation in a variety of pathologies also occurs.”
BackgroundMnDPDP for MR imaging of the liver
Rummeny, E. J., Torres, C. G., Kurdziel, J. C., et al. (1997) · Acta Radiologica · doi:10.1080/02841859709172394 · Cited by 76
In Vivo Cellular Imaging for Translational Medical Research
Arbab, A. S., Janic, B., Haller, J., Pawelczyk, E., Liu, W. X., & Frank, J. A. (2009) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/157340509787354697 · Cited by 71
“In all cases introduction of exogenous agents in allogenic or autologous cells is restricted by the FDA for use in humans [16, 24].”
BackgroundCetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy
Chu, I., Tseng, S., & Chou, M. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80134 · Cited by 76
“Due to their superior magnetic properties, superparamagnetic iron oxide nanoparticles (SPIONs), which are T 2 contrast agents, can significantly shorten the longitudinal (T 1 ) and transverse (T 2 ) magnetic relaxation time of water protons, thereby providing a dark negative signal intensity in the images.(27) SPIONs…”
Determination of Plasma Protein Adsorption on Magnetic Iron Oxides: Sample Preparation
Thode, K., Lück, M., Semmler, W., Müller, R. H., & Kresse, M. (1997) · Pharmaceutical Research · doi:10.1023/a:1012104017761 · Cited by 74
Canet‐Soulas, E., Revel, D., Forrat, R., Baldy, C., de Lorgeril, M., Sebbag, L., Vallée, J., Didier, D., & AMIEL, M. (1993) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(93)90241-5 · Cited by 70
BIOMEDICAL APPLICATIONS OF MAGNETIC NANOPARTICLES
Wu, A., OU, P., & Zeng, L. (2010) · NANO · doi:10.1142/s1793292010002165 · Cited by 75
Copper oxide nanoparticles as contrast agents for MRI and ultrasound dual-modality imaging
Perlman, O., Weitz, I. S., & Azhari, H. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/15/5767 · Cited by 75
Adamiano, A., Iafisco, M., Sandri, M., Basini, M., Arosio, P., Canu, T., Sitia, G., Esposito, A., Iannotti, V., Ausanio, G., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.04.040 · Cited by 71
Shiozawa, M., Lefor, A. K., Hozumi, Y., et al. (2012) · Breast Cancer · doi:10.1007/s12282-011-0327-9 · Cited by 67
“It has also been reported that ferucarbotran, which is the SPIO employed in this study, is sequestered by hepatic Kupffer cells [18].”
BackgroundKim, S. H., Lee, J. M., Lee, J. M., et al. (2006) · European Radiology · doi:10.1007/s00330-006-0193-6 · Cited by 66
Murakami, T., Imai, Y., Okada, M., et al. (2011) · Oncology · doi:10.1159/000333267 · Cited by 61
Multifunctional hollow nanoparticles based on graft-diblock copolymers for doxorubicin delivery
Lu, P.-L., Chen, Y., Ou, T.-W., Chen, H., Tsai, H., Wen, C.-J., Lo, C.-L., Wey, S., Lin, K., Yen, T., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.051 · Cited by 61
“Of note, liver Kupffer cells can rapidly remove particles from the circulation [19], and thismayaccount for the radioactivity signals observed in the liver following the administration ofmultifunctional and normal nanoparticles.”
BackgroundBatir, D. M., Boev, M., Cioancă, O., Lungu, I. I., Marin, G.-A., Burlec, A. F., Mitran, A.-M., Mircea, C., & Hăncianu, M. (2025) · Antioxidants · doi:10.3390/antiox14040489 · Cited by 66
Poeckler-Schoeniger, C., Koepke, J., Gueckel, F., et al. (1999) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(98)00180-5 · Cited by 60
Advances in functional and molecular MRI technologies in chronic liver diseases
Zhou, I. Y., Catalano, O. A., & Caravan, P. D. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.020 · Cited by 58
“SPIO particles, on the other hand, are referred as negative contrast agents due to their susceptibility effect which causes local magnetic field inhomogeneities and a resultant signal reduction on T2- or T2*-weighted images [32, 33].”
BackgroundSharkey, J. W., Lewis, P. J. S., Barrow, M., Alwahsh, S. M., Noble, J., Livingstone, E. J., Lennen, R. J., Jansen, M. A., Carrión, J. G., Liptrott, N. J., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.01.003 · Cited by 56
“, SPIONs released from necrotic cells) are naturally cleared by the reticuloendothelial system, including Kupffer cells [28], thereby providing the possibility of false-positive MRI hypointense signals from host cells.”
BackgroundOptimization and Validation of FePro Cell Labeling Method
Janic, B., Rad, A. M., Jordan, E. K., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005873 · Cited by 56
“Superparamagnetic iron oxide nanoparticles (SPION), such as ferumoxides, are a class of MRI contrast agents used for imaging pathology in the liver [1], and have also been used as an ex vivo cell labeling agent for various types of mammalian cells for in vivo cellular MRI.”
BackgroundAdvances in Polymeric and Inorganic Vectors for Nonviral Nucleic Acid Delivery
Sunshine, J. C., Bishop, C. J., & Green, J. J. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.14 · Cited by 55
Wang, K., Li, L., Xu, X., Lu, L., Wang, J., Wang, S., Wang, Y., Jin, Z., Zhang, J. Z., & Jiang, Y. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b18648 · Cited by 61
Gao, X., Luo, & Wang (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s32804 · Cited by 53
“35 Moreover, after cellular internalization, hydrolytic enzymes degraded intracellular SPION, and the nanoparticles consequently lost their capacity for contrast enhancement.”
Imaging of HCC—Current State of the Art
Schraml, C., Kaufmann, S., Rempp, H., et al. (2015) · Diagnostics · doi:10.3390/diagnostics5040513 · Cited by 52
“Malignant lesions tend to contain less Kupffer cells and therefore appear less hypointense than healthy liver tissue in SPIO imaging [43,44].”
BackgroundButoescu, N., Seemayer, C. A., Palmer, G., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2701 · Cited by 50
“The magnetic properties of this system come from the encapsulated SPIONs, which are nearly identical to the iron oxide used as a contrast agent in humans [11-13].”
BackgroundKim, Y. K., Kim, C. S., Lee, Y. H., et al. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.182.5.1821217 · Cited by 49
Mn‐DPDP enhancement patterns of hepatocellular lesions on MR images
Vogl, T. J., Hamm, B., Schnell, B., et al. (1993) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880030110 · Cited by 48
Contrast agents for MR imaging of the liver
Low, R. N. (1997) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880070109 · Cited by 48
Nakamura, H., Ito, N., Kotake, F., et al. (2000) · Journal of Gastroenterology · doi:10.1007/s005350070022 · Cited by 47
“(1) Tumor detection rate by each examination method (dynamic CT, plain MRI, Gd dynamic MRI, and SPIO-MRI) (2) Diagnostic accuracy (3) Comparison among rates of detection of tumors with varying nodular diameters (4) Intratumor blood flow patterns and detection rates (5) Detection rate for each SPIO-MRI sequence (6) His…”
Method
Metadata
- Authors
- Ferrucci, J. T., & Stark, D. D.
- Affiliations
- Massachusetts General Hospital (US)
- ORCID
- Stark, D D
- Venue
- American Journal of Roentgenology
- Publisher
- American Roentgen Ray Society
- Published
- 1990-11
- Volume
- 155
- Issue
- 5
- Pages
- 943-950
- ISSN
- 0002-9580 (ISSN-L)
- 0361-803X
- 1546-3141
- OpenAlex
- W2068366961
- Cited by
- 279
- References
- 0
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 2 · 2020: 6 · 2019: 6 · 2018: 7 · 2017: 11 · 2016: 6 · 2015: 18 · 2014: 9 · 2013: 10 · 2012: 18
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Roentgenology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Physical Sciences › Engineering › Biomedical Engineering › Characterization and Applications of Magnetic Nanoparticles
- Keywords
- superparamagnetic iron oxide nanoparticles, MRI contrast agents, liver tumors, splenic neoplasms, Kupffer cells, T2 relaxation, tumor detection, reticuloendothelial system, dose escalation, contrast-to-noise ratio, gradient-echo imaging, iron metabolism
- MeSH terms
- Animals, Humans, Image Enhancement, Iron, Liver Diseases, Magnetic Resonance Imaging, Oxides, Splenic Neoplasms, Ferrosoferric Oxide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
